LUCD — Lucid Diagnostics Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1799011 ·
Last close
$1.00
Market Cap
$190.95M
52W High
$1.23
52W Low
$0.86
ADV30
1,320,644
Next earnings
2026-11-11
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,256,000 -369,000 -12,114,000 -13,909,000 34,080,000 27,876,000 30,080,000
Dec 2025 1,504,000 -356,000 -14,011,000 -16,266,000 40,445,000 34,705,000 29,509,000
Sep 2025 1,211,000 -486,000 -11,759,000 -10,397,000 53,198,000 47,332,000 27,363,000
Jun 2025 1,163,000 -400,000 -11,384,000 -4,439,000 38,670,000 31,123,000 30,808,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-46,121,000
Investing CF
$-319,000
Financing CF
$49,078,000
CapEx
$-319,000
Dividends Paid
Buybacks
$-17,000
EPS Diluted TTM
$-0.45
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-297,963,000
Inventory
$469,000
Receivables
$689,000
ST Investments
EBIT TTM
$-44,991,000
Pretax Income TTM
$-45,011,000
Interest Exp TTM
$20,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,445,000
EBITDA
$-49,808,000
Free Cash Flow
$-26,429,124
Enterprise Value
$181,385,728
Total Cash
$34,472,000
Total Debt
$24,909,000
Shares Out
190,948,730
Trailing EPS
$-0.43
Book Value
$0.06
ROE
-556.3%
ROA
-81.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,706,000 -49,640,000 -58,010,000 40,445,000 29,509,000 -46,485,000
Dec 2024 4,346,000 -46,052,000 -45,529,000 30,715,000 25,324,000 -44,140,000
Dec 2023 2,428,000 -48,482,000 -52,666,000 27,270,000 29,581,000 -32,817,000
Dec 2022 377,000 -56,251,000 -56,171,000 32,509,000 9,462,000 -29,685,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.16

Peers — same industry

TickerNameMarket CapLastDaily %
PDEX PRO DEX INC $213.47M $66.86
AVHHL AVITA Medical, Inc. $219.58M $1.42
STIM Neuronetics, Inc. $220.21M $2.89
ZJYL Jin Medical International Ltd. $223.94M $3.04
NYXH Nyxoah SA $162.12M $1.62

News headlines (Yahoo Finance, 1h cache)

Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript
2026-08-20 13:58 · Yahoo
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-14 12:00 · Yahoo
Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ...
2026-08-13 23:06 · Yahoo
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 13:10 · Yahoo
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-13 12:00 · Yahoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
2026-08-05 12:36 · Yahoo
Lucid Diagnostics to Participate in Upcoming Investor Conferences
2026-08-04 12:30 · Yahoo
Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results
2026-06-02 13:57 · Yahoo
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary
2026-08-14 02:07 · Yahoo
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-15 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.